FDA
-
-
-
-
-
-
-
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
-
-
-
-
-
-
-
CervoMed shares new data showing drug benefits for dementia patients
-
-
-
-
-
-
-
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
-
-
-
-
-
-
-
CervoMed gains FDA alignment for dementia with Lewy bodies drug trial
-
-
-
-
-
-
-
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
-
-
-
-
-
-
-
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

